ASSENT PLUSAssessment of the Safety & Efficacy of a New Thrombolytic agent. A trial comparing dalteparin (TNKase™) to unfractionated heparin (UH) as an adjunct to rt-PA for improving coronary artery patency and outcome in patients with acute myocardial infarction (MI).
Conclusion Better blood flow with dalteparin than UH; no difference in acute MIs or death.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.